Digital Biomarkers Market Size & Share 2026-2035

Digital Biomarkers Market Size

The global digital biomarkers market was valued at USD 4.8 billion in 2025 and is projected to grow from USD 6 billion in 2026 to USD 60.6 billion by 2035, expanding at a CAGR of 29.2%, according to the latest report published by Global Market Insights Inc.

The growing advancements in sensor technologies, rising adoption of remote patient monitoring solutions, and increasing integration of AI-enabled analytics in clinical research are collectively driving the revenue growth in the market.

The digital biomarker market is said to be on high growth momentum as technology developers, pharmaceutical companies, and research institutions are investing more in the development of advanced data-driven health technology. Companies are working hard to take their R&D activities to the next level to deliver advanced digital endpoints that are validated and reliable to improve patient health and efficiency in clinical trials and support various precision medicine projects.

For example, various research studies published in recent times have shown positive outcomes from AI-based gait, speech, and cognitive digital biomarkers for neurodegenerative diseases, where there has been a lack of validated endpoints. These developments are likely to take the digital biomarker market to greater heights in the future. The top 5 players in this market are Ametris, AliveCor, Altoida, Evidation Health Inc., and IXICO plc.

Moreover, the high prevalence of chronic diseases is benefiting the rise in the global market, reaching new heights. For instance, according to the World Health Organization (WHO), 41 million people die annually because of noncommunicable diseases (NCDs), which account for 74% of the total mortality globally.

Of these figures, 17 million are attributed to premature death, with 86% of the fatalities recorded in the middle- and low-income economies globally. This increasing disease burden indicates the need for effective diagnostics to combat the diseases, especially in areas that lack resource availability. These trends justify the development and global integration of new tools such as digital biomarkers that will further facilitate the monitoring and control of chronic disease management, even in areas with little or no access to healthcare services.

Digital biomarkers are physiological, behavioural, or environmental data that are collected and recorded by means of digital devices such as smartphones, wearables, or other sensor-equipped tools. By means of extrapolated data, these biomarkers assess one’s health, disease stage, as well as treatment effects.

Digital Biomarkers Market Trends

• The incorporation of artificial intelligence and machine learning in healthcare has propelled the evolution of digital biomarkers, resulting in better forecasting, reaching a wider population, and a tailored approach to the healthcare sector.
• AI and ML algorithms are multidisciplinary approaches that leverage huge amounts of data gathered from wearables, smartphones, and other digital devices by identifying subtle changes in monitored behaviors as well as physiological metrics. For example, Li et al. (2020) have suggested that these technologies can identify atrial fibrillation from ECG recordings obtained from smartwatches and can even anticipate variations in multiple sclerosis patients by carrying out gait and speech analyses.
• In parallel, AI algorithms are able to analyze multimodal datasets and offer improvement indicators for mitigating diseases, such as Alzheimer’s or diabetes, and even mental disorders, where symptoms are minimal or absent. ML algorithms that utilize speech-based biomarkers are one such example of assessing cognitive decline in patients at a much earlier stage.
• In addition, ML algorithms can make specialized health suggestions by merging specific biomarker trends with larger datasets. This is useful in chronic diseases to tailor the treatment by forecasting the response to medication, thus optimizing the patient’s care.

Digital Biomarkers Market Analysis

Based on type, the market is segmented into wearable, mobile based applications, sensors, and other types. The wearable segment dominated the market, accounting for 42.5% of the revenue share in 2025.

• Wearable devices provide the capability to track physiological and behavioral indicators such as heartbeats, total hours of sleep, degree of physical activity, and even glucose concentration on a daily basis, non-stop. Such unending data greatly surpasses the information offered by sporadic clinical visits.
• Also, the change that is slightly captured in the biomarkers is done so by wearables, and this helps in ruling out the disease at an early stage so that treatment can be performed on time. For example, wearable ECG monitors can detect atrial fibrillation, which is one of the signs of the disease, before other main symptoms are detected.
• Moreover, wearables reduce health diagnostic tests to a more comfortable level than a blood test or even invasive sensors, so consumers can be more willing to use them, which in turn facilitates market growth.

Based on clinical practice, the digital biomarkers market is bifurcated into diagnostic digital biomarkers, monitoring digital biomarkers, predictive and prognostic digital biomarkers, and other clinical practices. The monitoring digital biomarkers segment accounted for a 45.8% market share in 2025 and is projected to grow significantly, reaching USD 27.8 billion by 2035.

• Disease prevention can be accomplished with the help of biomarkers and wearable technology. Predictive medicine suits them perfectly. If the alterations are fairly vague in terms of behavior or physiology, digital monitoring assists in diagnosing the condition earlier on, which allows for timely actions to be made that will consequently have a significantly better outcome for the patient when compared to more progressive and chronic illnesses such as diabetes or Alzheimer’s.
• The use of digital biomarker monitoring reveals a substantial amount of data as well as in-depth insight into the patient’s health. This approach allows for interventions and changes to be made significantly faster, which reduces the chances of health-related complications.
• Another significant advantage is the possibility of wearing devices instead of having them implanted, as most digital biomarker monitoring systems use wearable devices or mobile phones.
• Compared to other diagnostic approaches, these devices are considerably more comfortable and encourage users to be more compliant. With these factors in mind, it is clear to see how they can aid in the advancement of the market.

Based on therapeutic area, the digital biomarkers market is bifurcated into cardiovascular and metabolic disorders (CVMD), diabetes, respiratory disorders, psychiatric disorders, sleep and movement diseases, neurological disorders, musculoskeletal disorders, and other therapeutic areas. The cardiovascular and metabolic disorders (CVMD) segment accounted for a 22.6% market share in 2025.

• This aims to extend the use of digital biomarkers in diagnosing and monitoring diseases such as diabetes and cardiovascular and metabolic disorders. Wearable technology such as monitoring devices may identify atypical heart patterns such as fibrillation, which increases stroke and heart failure risk.
• Early indications of diabetes or metabolic syndrome may be identified with the help of continuous glucose monitors (CGM), which detect unusual blood sugar patterns.
• CVMD patients can leverage continuous monitoring of physiological parameters that allow true monitoring of the evolution of the disease by healthcare professionals.
• Online platforms combined with blood pressure monitors can determine the movement towards hypertension, and the wearable weighing commercially available physical activity and heart rate variability shows cardiovascular fitness and recovery rate after surgery or heart attack.
• Moreover, employing artificial intelligence can further smooth the process of medicine through algorithms that integrate analytics from digital biomarkers such as heart rate, blood oxygen saturation percentage, and glucose levels. Such capabilities have proven useful in emergencies by allowing doctors to predict myocardial infarctions, strokes, and hypoglycemic episodes.
• Predicting capability means appropriate medical care can be provided at the right time, which in some instances helps in reducing loss of lives and therefore leads to growth in the market.

Based on end use, the digital biomarkers market is bifurcated into healthcare providers, payers, pharmaceutical and biotechnology companies, and academic and research institutions. The healthcare providers segment accounted for a 38.4% market share in 2025.

• This dominance is driven by the rapid integration of wearable devices, mobile health applications, and sensor‑based digital tools into daily clinical workflows, enabling providers to adopt more proactive and data‑driven approaches to patient management.
• The use of digital tools, apps, and devices, wearable devices for instance, has allowed healthcare professionals to predict sickness onset alongside changes in vital signs and behaviors that are more in-depth. Tracking heart conditions such as atrial fibrillation or even early onset of diabetes or mental disorders before they manifest into the full-blown disease makes the process of treatment easier and faster.
• Digital biomarkers also assist healthcare practitioners in treating chronic illnesses such as hypertension, diabetes, and cardiovascular issues. When crucial indicators such as blood pressure, heart variability, or glucose levels are monitored, treatment can be adjusted, which aids in further growing the market for digital biomarkers with time. As providers continue investing in digital health infrastructure, wearables, and AI‑powered analytics, the segment is expected to maintain its leading position.

North America Digital Biomarkers Market

• North America accounted for the largest share of the market in 2024, supported by its advanced provider networks, high adoption of connected wearables, and early integration of AI‑enabled analytics across clinical workflows and trials.
• The region benefits from well‑established regulatory systems, principally the U.S. FDA and Health Canada, that are increasingly supportive of digital endpoints and remote monitoring, facilitating timely qualification and use of sensor‑derived measures in research and care models. This regulatory posture accelerates clinical validation and payer/provider confidence in digital biomarkers.
• A key driver of North America’s dominance is the substantial chronic disease burden, which amplifies demand for continuous, real‑time monitoring. With noncommunicable diseases accounting for the majority of mortality, driving urgency for earlier detection and proactive management, health systems and life‑science sponsors are scaling digital biomarker programs across cardiometabolic, neurological, and respiratory conditions.
• With sustained investment in AI/ML analytics and continued expansion of remote‑care models, North America is expected to maintain its leading position over the forecast period.

The U.S. digital biomarkers market size reached USD 1.8 billion in 2025, growing from USD 1.4 billion in 2024.

• The emergent technological ecosystem within the U.S. provides an exceptionally fertile environment for the development, validation, and large-scale deployment of advanced digital biomarker solutions.
• Powered by the nation’s strong backbone of artificial intelligence, machine learning, cloud computing, and data integration capabilities, both established tech giants and new digital-health ventures are accelerating innovation in real-time physiological and behavioural signal analysis. This deep technological foundation positions the U.S. as a global frontrunner in digital biomarker R&D and clinical translation.
• Widespread adoption of wearable technologies, including smartwatches, fitness trackers, and continuous glucose monitors (CGMs), further amplifies the country’s leadership in digital biomarkers.
• These devices generate high-frequency, real-world health signals that enable granular tracking of vital signs, activity patterns, sleep cycles, and cardiometabolic markers. The rapid surge in wearable use across both consumer and clinical settings strengthens the U.S. digital biomarker ecosystem by supporting population-scale data collection, enhanced predictive algorithms, and early identification of disease risk.
• The combination of advanced technological infrastructure, strong regulatory backing, high consumer adoption of wearables, and growing chronic-disease burden solidifies the U.S. as the primary hub for digital biomarker development.

Europe Digital Biomarkers Market

Europe market accounted for USD 1 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe held a strong and well-established position in the market in 2025, supported by its rapidly expanding digital-health ecosystem, strong hospital networks, and widespread integration of sensor-based monitoring tools. The region benefits from a mature healthcare infrastructure and rising adoption of digital healthcare solutions.
• European health systems emphasize early diagnosis, structured chronic-disease management, and standardized clinical pathways, enabling broad uptake of digital biomarkers across cardiology, neurology, respiratory care, and metabolic disease monitoring.
• The increasing use of smartphone-based applications, wearable sensors, and connected diagnostic platforms supports consistent deployment of digital biomarkers across both primary and specialty care settings.
• Moreover, Europe’s strategic focus on early intervention, equitable access to digital health services, and integration of digital biomarkers into chronic-disease pathways ensures sustained demand and reinforces the region’s long-term leadership in the global digital biomarkers landscape. Continued investment in mobile health technologies, cloud-based analytics, and digital therapeutics is expected to further strengthen Europe’s market position.

The digital biomarkers market in UK is expected to experience significant and promising growth from 2026 to 2035.

• The UK benefits from one of the world's most advanced and structured public healthcare systems, the National Health Service (NHS), which is increasingly integrating digital health technologies and digital biomarkers into mainstream care.
• This strong institutional foundation, combined with national digital‑health strategies, has accelerated the adoption of AI‑driven analytics, remote patient monitoring tools, wearable‑based diagnostics, and cloud‑enabled health platforms across hospitals and primary care settings.
• Growing emphasis on early diagnosis, long‑term condition management, and preventive care strengthens the UK’s role in advancing digital biomarker deployment.
• With millions of residents affected by chronic diseases and rare conditions, NHS programs leveraging AI‑driven analytics, symptom‑tracking platforms, and wearable‑derived physiological data are helping clinicians optimize treatment, reduce demand on acute care services, and support real‑time, patient‑centric monitoring.

Asia Pacific Digital Biomarkers Market

The Asia-Pacific region is projected to show lucrative growth of about 29.9% during the forecast period.

• Asia Pacific is rapidly emerging as one of the fastest-growing regions in the market, driven by its vast population base, rising chronic-disease burden, and accelerated adoption of digital health technologies across both developed and emerging economies.
• The region includes technologically advanced markets such as Japan, South Korea, Singapore, and Australia, where digital health integration is highly mature, as well as fast-growing economies such as China, India, and Southeast Asia, which are significantly expanding their digital infrastructure and clinical innovation capacity.
• The clinical burden of chronic diseases, including cardiovascular disorders, diabetes, neurological conditions, and respiratory illnesses, remains substantial across Asia Pacific, driving strong demand for continuous, real-time monitoring solutions.
• Digital biomarkers derived from wearables, mobile health applications, and remote monitoring platforms are increasingly being used to support early detection, risk stratification, and long-term disease management at scale.
• With high smartphone penetration and growing reliance on mobile-based health solutions, the region is experiencing rapid uptake of patient-centric digital monitoring tools that enhance care quality and accessibility.
• With its large and aging population, expanding healthcare access, rising investments in digital health, and accelerated deployment of wearable-based monitoring platforms, Asia Pacific is expected to remain one of the fastest-growing regions in the global digital biomarker market over the forecast period.

Japan digital biomarkers market is anticipated to witness lucrative growth between 2026 and 2035.

• Japan stands at the forefront of technological innovation, with globally recognized strengths in robotics, artificial intelligence, advanced electronics, and precision engineering. This deep‑rooted technological foundation significantly accelerates the development, integration, and scalability of digital biomarkers across the country.
• Japan’s leadership in sensor technology, smart wearables, and AI‑driven diagnostic algorithms enables highly accurate, real‑time data capture, strengthening the reliability and clinical utility of digital biomarker platforms used in healthcare and research.
• The country’s rapidly aging population drives substantial demand for digital biomarker‑enabled healthcare solutions. Japan faces high prevalence rates of chronic and age‑associated diseases, including cardiovascular disorders, diabetes, neurodegenerative conditions such as Alzheimer’s disease, and lifestyle‑related illnesses.
• As disease complexity rises in its super‑aged society, digital biomarkers offer an effective clinical response pathway by enabling continuous remote monitoring, early detection of deterioration, and proactive management of long‑term conditions.

Latin America Digital Biomarkers Market

Brazil is experiencing significant growth in the digital biomarkers industry.

• Brazil represents one of the most important and rapidly expanding digital biomarker markets in Latin America, driven by its large population, rising chronic-disease burden, and growing national focus on digital health adoption across both public and private healthcare systems.
• The country’s strong uptake of digital health wearables and remote-monitoring tools reflects a broader shift toward modern, data-driven healthcare delivery.
• The epidemiological burden of chronic diseases, including cardiovascular disease, diabetes, and respiratory disorders, continues to intensify in Brazil, creating sustained demand for digital biomarkers that support continuous monitoring, early detection, and personalized disease management.
• As remote patient monitoring (RPM) becomes a critical component of value-based care models in the country, digital biomarkers derived from wearables, connected sensors, and mobile apps are increasingly used to guide timely intervention and improve patient outcomes.
• With rising investment in digital-health infrastructure, strong consumer adoption of wearables, and accelerating integration of AI-based analytics, Brazil is positioned to remain a key growth market for digital biomarkers in Latin America.

Middle East and Africa Digital Biomarkers Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2035.

• Saudi Arabia is rapidly positioning itself as a strategic hub for digital health innovation, driven by national ambitions to strengthen medical infrastructure and diversify the economy under the Vision 2030 framework.
• The government’s strong investment in digital transformation across healthcare, biotechnology, and data ecosystems is creating a fertile environment for the integration and expansion of digital biomarkers within the country. This commitment reflects the nation’s broader goal of elevating global competitiveness and adopting advanced health technologies that set new standards across the Gulf region.
• With ongoing investments, a growing regulatory push for digital innovation, and expanding national infrastructure for data‑driven care, Saudi Arabia is positioned to become one of the most influential digital biomarker markets in the Middle East.
• The alignment of Vision 2030 goals with digital health adoption ensures long‑term support for emerging technologies, driving strong future growth and establishing the kingdom as a regional leader in digital biomarker implementation and innovation.

Digital Biomarkers Market Share

• The digital biomarkers industry is highly competitive, characterized by a blend of established global leaders and rapidly advancing innovators developing next-generation sensor-based, AI-driven, and real-world-data solutions. Market participants are strengthening their competitive positions through advancements in wearable-based data capture, multimodal biomarker analytics, clinical-grade validation, and strategic collaborations with pharmaceutical companies, healthcare providers, and academic research institutions.
• Top players such as Ametris, AliveCor, Altoida, Evidation Health Inc., and IXICO plc collectively account for approximately 40% of the global digital biomarker market. These companies benefit from strong technology portfolios spanning AI-powered physiological monitoring, cognitive and neurological biomarker assessment, validated ECG-based cardiac biomarkers, and large-scale digital health data networks used to support clinical trials, decentralized research, and chronic-disease management programs.
• Overall, competitive dynamics within the digital biomarker market are shaped by rapid technological innovation, increasing adoption of AI-enabled measurement tools, and expanding use of real-world data in regulatory submissions and clinical development.

Digital Biomarkers Market Companies

Some of the eminent market participants operating in the digital biomarkers industry include:

• Ametris
• AliveCor
• Altoida
• Amgen Inc.
• Adherium Limited
• Aural Analytic
• Brainomix
• Biogen
• Clario
• Empatica Inc.
• Evidation Health Inc.
• IXICO plc
• Koneksa
• Sonde Health, Inc.
• Vivo Sense

• Evidation Health

Evidation Health is a leading force in the digital biomarker ecosystem, distinguished by its vast real-world data networks and its ability to capture, analyze, and translate large-scale behavioural and physiological signals into clinically meaningful insights. The company partners extensively with pharmaceutical sponsors, research organizations, and healthcare systems to generate high-quality real-world evidence that advances clinical research and population-level disease understanding

• IXICO plc

IXICO plc is an established leader in neuroimaging-driven digital biomarker development, with deep specialization in neurological and neurodegenerative disorders. The company’s advanced imaging analytics platform supports clinical trials in Alzheimer’s disease and other CNS conditions, delivering high-fidelity digital endpoints that enhance patient stratification, disease-progression modelling, and therapeutic evaluation.

• Ametris

The company specializes in developing validated, scalable digital biomarkers derived from high-frequency physiological, behavioural, and real-world patient data streams. Its platforms are designed to support early disease detection, therapeutic-response monitoring, and longitudinal patient assessment across clinical and real-world environments.

Digital Biomarkers Industry News:

• In June 2024, AliveCor announced FDA clearance and the commercial launch of KAI12L AI technology and the Kardia 12L ECG System, the world’s first AI capable of detecting life-threatening cardiac conditions, including heart attacks, using a reduced lead set. This innovation enhances remote cardiac monitoring, enabling early detection and timely intervention, transforming cardiovascular care with accessible and efficient diagnostic solutions.
• In February 2023, ActiGraph and uMotif announced a strategic partnership to integrate ActiGraph’s wearable sensor technology with uMotif’s patient‑engagement platform, enabling highly patient‑centered solutions for clinical research. The collaboration brings together ActiGraph’s validated, research‑grade wearable devices and uMotif’s evidence‑based digital engagement tools to enhance data quality, improve patient compliance, and streamline decentralized and hybrid trial operations.

The digital biomarkers market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Wearable
• Mobile-based applications
• Sensors
• Other types

Market, By Clinical Practice

• Diagnostic digital biomarkers
• Monitoring digital biomarkers
• Predictive and prognostic digital biomarkers
• Other clinical practices

Market, By Therapeutic Area

• Cardiovascular and metabolic disorders (CVMD)
• Diabetes
• Respiratory disorders
• Psychiatric disorders
• Sleep and movement diseases
• Neurological disorders
• Musculoskeletal disorders
• Other therapeutic areas

Market, By End Use

• Healthcare providers
• Payers
• Pharmaceutical and biotechnology companies
• Academic and research institutions

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE